Physician profile
Michael J Adams
NPI 1235107012
$9,040.93
in general payments reported to CMS, 2019-2025
50 companies · $1,134 in 2025
The $1,134 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,483 · 2020: $1,120 · 2021: $1,872 · 2022: $1,478 · 2023: $1,256 · 2024: $699 · 2025: $1,134.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,089.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,088.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,359.22 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Astrazeneca Pharmaceuticals LP | $654.15 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $583.89 | 2019-2025 | |
| Lilly USA, LLC | $557.33 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Otsuka America Pharmaceutical, INC. | $477.94 | 2019-2025 | Rexulti |
| Amgen INC. | $464.31 | 2019-2025 | Otezla, Repatha, Prolia |
| Amarin Pharma, INC. | $397.10 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $340.77 | 2019-2025 | Trintellix |
| Glaxosmithkline, LLC. | $337.69 | 2019-2023 | Shingrix, Arexvy, Trelegy Ellipta |
| Allergan, INC. | $309.15 | 2019-2020 | |
| Novo Nordisk INC | $307.35 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Bausch Health US, LLC | $306.01 | 2019-2023 | Aplenzin |
| Lundbeck LLC | $256.83 | 2020-2024 | Rexulti |
| Biosense Webster, INC. | $196.56 | 2022 | |
| Astellas Pharma US INC | $186.71 | 2019-2021 |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Adams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.